Cantor Fitzgerald Weighs in on PVLA FY2026 Earnings

Palvella Therapeutics (NASDAQ:PVLA) – Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings estimates for shares of Palvella Therapeutics in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will post earnings per share of ($2.73) for the year. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share.

PVLA has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $38.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, April 30th. Chardan Capital initiated coverage on Palvella Therapeutics in a research report on Wednesday, April 9th. They set a “buy” rating and a $50.00 target price for the company. Canaccord Genuity Group lowered their target price on Palvella Therapeutics from $53.00 to $52.00 and set a “buy” rating for the company in a research report on Friday, May 16th. Scotiabank initiated coverage on Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price for the company. Finally, Jones Trading initiated coverage on Palvella Therapeutics in a research report on Tuesday, March 25th. They set a “buy” rating and a $45.00 target price for the company. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $46.29.

Palvella Therapeutics Stock Down 3.5%

NASDAQ PVLA opened at $25.32 on Wednesday. The company has a market cap of $279.94 million, a P/E ratio of -2.09 and a beta of -0.10. Palvella Therapeutics has a one year low of $6.20 and a one year high of $29.27. The firm’s 50 day moving average price is $23.54.

Palvella Therapeutics (NASDAQ:PVLA) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.40) by $2.66.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins purchased 2,500 shares of the business’s stock in a transaction dated Wednesday, April 9th. The shares were purchased at an average price of $20.13 per share, for a total transaction of $50,325.00. Following the completion of the purchase, the director now owns 183,171 shares in the company, valued at approximately $3,687,232.23. This represents a 1.38% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 20.50% of the company’s stock.

Hedge Funds Weigh In On Palvella Therapeutics

Several institutional investors have recently made changes to their positions in PVLA. BML Capital Management LLC purchased a new position in shares of Palvella Therapeutics during the fourth quarter valued at $506,000. Geode Capital Management LLC purchased a new position in Palvella Therapeutics in the fourth quarter valued at about $171,000. ADAR1 Capital Management LLC purchased a new position in Palvella Therapeutics in the fourth quarter valued at about $1,736,000. Renaissance Technologies LLC purchased a new position in Palvella Therapeutics in the fourth quarter valued at about $256,000. Finally, Blue Owl Capital Holdings LP purchased a new position in Palvella Therapeutics in the fourth quarter valued at about $3,001,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.